“India
has shown great interest in advancing the science of stem cell
biology”
—David Smoller,
president, Research Biotechnology Business, Sigma Aldrich
Sigma Aldrich, the US
based life science and high technology company, has recently announced
the launch of an online web portal that provides researchers with
immediate access to its extensive portfolio of over 1,100
industry-leading products developed specifically for advanced stem cell
research. In addition, a team of regenerative medicine experts has been
retained to identify and develop new and promising technologies in this
growing area. This comes in the wake of lifting of the ban on
stem cell research and companies showing willingness to realize their
potential in the area. In an interview with David Smoller, president,
Sigma Aldrich, we find out more.
Sigma’s
division of regenerative medicine has been set up recently? Elaborate
on the plans of the division?
The regenerative medicine program within the research biotech division
of Sigma-Aldrich was established in January, 2009. The mission of the
regenerative medicine program is to provide a portal for the stem cell
research community to access Sigma-Aldrich’s broad portfolio
of life science products and services. Now these scientists have a
single location to research and source the products they need to carry
out their research. Further, the regenerative team will help to develop
new products and services to overcome the limitations of existing
products available to stem cell researchers.
What are the new
products launched by Sigma Aldrich for stem cell research?
To date, the products launched by Sigma Aldrich include an expanded
line of research antibodies useful for understanding genes that play a
role in stem cell self-renewal and differentiation, and a new line of
3D scaffolds for growing stem cells in an environment that mimics
in-vivo conditions. This year, the regenerative medicine group plans to
launch many more cutting-edge products.
Is this on the
backdrop of the recent lifting of federal restriction on stem cell
research? How is it going to impact the business of companies such as
yours in the US?
The impact from the lifting of federal restrictions is difficult to
measure because privately financed stem cell research continues to play
a significant role. We believe that the $10 billion of economic
stimulus funding targeted at the NIH will have a significant impact in
terms of stem cell research; this stimulus will increase available
money for existing and new stem cell researchers to conduct more
experiments.
How do you see the
stem cell research in India vis-a-vis the US?
Since the creation of the task force on “Stem Cell Biology
and Regenerative Medicine” in 2003, and the opening of the
Manipal Institute of Regenerative Medicine in 2007, India has shown
great interest and capability in advancing the science of stem cell
biology, not only in basic research but also in the development of
potentially lifesaving therapies. For research in any country the key
issues are the availability of funding and the availability of a
talented pool of scientists, and on both these counts we believe India
is primed to lead.
How do you view
competition from other players in this segment and how do you
differentiate yourself?
Our competition also sees the opportunity in providing life sciences
tools to stem cell scientists. It is our opinion that Sigma
Aldrich’s efforts at developing new research tools along with
our competitors will only benefit stem cell researchers. In this
competitive market, we will differentiate ourselves by providing new
technologies that address the limitations our customers face today, and
by providing streamlined access to our products so that researchers can
easily find what they need.
What is the marketing
strategy for the products? How much revenues do you hope to generate
and how much are they going to contribute to the company’s
gross revenue?
We don’t typically comment on revenue projections within
Sigma Aldrich divisions. However, we do expect this research market to
grow at double digit rates year over year. Our strategy consists of
several elements like aggressive launch of new products, expanding
technical resources available to our customers, strengthening our
presence in the stem cell research community, and continue to
collaborate with leading stem cell research institutions in India and
other nations.
What are the future
plans of the research biotech division of Sigma Aldrich?
The research biotech division of Sigma Aldrich will continue to invest
in capital and people to ensure our service to this and other growing
markets. Further, as we always have done, we will acquire the necessary
technologies and product content to address the future needs of our
customers.
Stem cell lines
The portal’s expanding line of cutting-edge technologies for
stem cell research includes the industry’s most
highly-validated shRNA library, the Mission RNAi portfolio, which
enables gene silencing across a wide range of cellular targets. The
site also features the CompoZr zinc finger nuclease (ZFN) reagent
platform which enables researchers, for the first time, to target and
precisely manipulate the genome of both differentiated cells and stem
cells, resulting in cell lines or whole organisms with permanent,
targeted gene deletions, insertions, or corrections. A complete line of
polyclonal and monoclonal antibodies is available, including the
Prestige Antibodies collection, considered the industry’s
most highly characterized line of antibodies. Stemline animal
serum-free media, essential for many researchers in the expansion and
maturation of cell lines, is also available.
|
Shalini Gupta